Form 4: Emergent BioSolutions Director Marvin L. White Reports Stock and Option Awards

Director Marvin L. White reports the acquisition of restricted stock units and stock options in Emergent BioSolutions Inc. on April 30, 2025.

Summary

• On April 30, 2025, Marvin L. White, a director of Emergent BioSolutions Inc., reported transactions involving the company's securities.
• White acquired 34,403 shares of common stock through restricted stock units (RSUs) and 15,824 stock options.
• The RSUs and stock options were granted under the company's Stock Incentive Plan for Board and Committee service.
• The RSUs represent the right to receive one share of Emergent BioSolutions Inc. common stock upon vesting.
• The shares underlying the RSUs and options will vest on the day prior to the one-year anniversary of the grant date, contingent on White remaining a member of the board of directors.
• The exercise price of the stock options is $5.45.
• Following these transactions, White beneficially owns 88,495 shares of common stock and 41,572 derivative securities.

Sentiment

Score: 6

Explanation: The document reflects a neutral sentiment as it is a standard disclosure of stock and option awards to a director. It doesn't contain any information that would significantly impact the company's outlook positively or negatively.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting requirements incentivize continued service on the board of directors.

Future Outlook

The vesting of the RSUs and stock options is contingent on the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

Industry Context

This filing is a routine disclosure of stock and option awards to a director, which is a common practice in publicly traded companies to incentivize and retain board members.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for directors in publicly traded companies, such as Emergent BioSolutions.
• The vesting schedules and terms are generally comparable to those offered by similar companies to their board members.
• Companies like Moderna, Novavax, and BioNTech also utilize stock options and RSUs as part of their director compensation packages.

Stakeholder Impact

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.

Key Dates

Keywords

Emergent BioSolutions, Director, Stock Options, RSUs, Form 4, Beneficial Ownership, Securities, Incentive Plan